Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EPS (Basic) (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EPS (Basic) for 4 consecutive years, with -$0.41 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) fell 10.81% to -$0.41 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.89, a 24.34% decrease, with the full-year FY2024 number at -$2.06, down 31.21% from a year prior.
  • EPS (Basic) was -$0.41 for Q3 2025 at Centessa Pharmaceuticals, down from -$0.37 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.2 in Q1 2025 to a low of -$0.91 in Q4 2024.
  • A 4-year average of -$0.46 and a median of -$0.4 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): surged 60.87% in 2023, then crashed 145.95% in 2024.
  • Centessa Pharmaceuticals' EPS (Basic) stood at -$0.45 in 2022, then rose by 17.78% to -$0.37 in 2023, then plummeted by 145.95% to -$0.91 in 2024, then surged by 54.95% to -$0.41 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's EPS (Basic) are -$0.41 (Q3 2025), -$0.37 (Q2 2025), and -$0.2 (Q1 2025).